{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:33:47Z","timestamp":1793306027518,"version":"4.5.0"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000005","name":"US Department of War","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.euo.2026.08.004","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T03:58:58Z","timestamp":1789531138000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Risk-dependent Benefit of Adjuvant Pembrolizumab in High-risk Clear Cell Renal Cell Carcinoma: A Multi-institutional Study"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4079-9051","authenticated-orcid":false,"given":"Daniel D.","family":"Shapiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel F.","family":"Roadman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viraj A.","family":"Master","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Peyton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew G.","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon J.","family":"Manley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe E.","family":"Spiess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paz","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dattatraya","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Dehghanmanshadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reagan","family":"Amason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max J.","family":"Bouvette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Blittschau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendrick H.","family":"Yim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Abreu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishnavi","family":"Jayakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn O.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wade J.","family":"Sexton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin Jason","family":"Abel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.08.004_b0005","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/bju.15673","article-title":"Risk models for recurrence and survival after kidney cancer: a systematic review","volume":"130","author":"Usher-Smith","year":"2022","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2026.08.004_b0010","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae): kidney cancer. National Comprehensive Cancer Network Web site. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf."},{"key":"10.1016\/j.euo.2026.08.004_b0015","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1056\/NEJMoa1611406","article-title":"Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy","volume":"375","author":"Ravaud","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.08.004_b0020","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1200\/JCO.2017.73.5324","article-title":"Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma","volume":"35","author":"Motzer","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.08.004_b0025","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1093\/annonc\/mdy454","article-title":"Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial","volume":"29","author":"Gross-Goupil","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2026.08.004_b0030","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.08.004_b0035","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall survival with adjuvant pembrolizumab in renal-cell carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.08.004_b0040","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.eururo.2025.02.020","article-title":"European Association of Urology guidelines on renal cell carcinoma: the 2025 update","volume":"87","author":"Bex","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.08.004_b0045","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(22)01658-0","article-title":"Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial","volume":"400","author":"Pal","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2026.08.004_b0050","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(22)02574-0","article-title":"Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial","volume":"401","author":"Motzer","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2026.08.004_b0055","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/S1470-2045(24)00211-0","article-title":"Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (Prosper ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study","volume":"25","author":"Allaf","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.08.004_b0060","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.eururo.2024.10.020","article-title":"Challenges and considerations in modern adjuvant therapy trials in renal cell carcinoma: a call to power","volume":"87","author":"Shapiro","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.08.004_b0065","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.urolonc.2024.06.018","article-title":"Adjuvant therapy for renal cell carcinoma: finding the signal in the noise","volume":"43","author":"Shapiro","year":"2025","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2026.08.004_b0070","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2026.44.7_suppl.LBA418","article-title":"Adjuvant pembrolizumab plus belzutifan versus pembrolizumab for clear cell renal cell carcinoma (ccRCC): the randomized phase 3 LITESPARK-022 study","volume":"44","author":"Choueiri","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.08.004_b0075","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1200\/JCO.19.00107","article-title":"Predicting renal cancer recurrence: defining limitations of existing prognostic models with prospective trial-based validation","volume":"37","author":"Correa","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.08.004_b0080","doi-asserted-by":"crossref","first-page":"271.e1","DOI":"10.1016\/j.clgc.2020.08.003","article-title":"Causal diagram techniques for urologic oncology research","volume":"19","author":"Shapiro","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2026.08.004_b0085","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), Version 6.0. National Institutes of Health, US Dept of Health and Human Services; 2025. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverseevents\/ctcae-v6.pdf."},{"key":"10.1016\/j.euo.2026.08.004_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115569","article-title":"Current status of adjuvant immunotherapy and relapse management in renal cell carcinoma: insights from a European Delphi study","volume":"225","author":"Gr\u00fcnwald","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euo.2026.08.004_b0095","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1007\/s00262-025-04230-w","article-title":"Real-world evidences on adjuvant Pembrolizumab for renal cell carcinoma: results from the multicenter real-world ARON-1 study","volume":"74","author":"Kopp","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.euo.2026.08.004_b0100","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000543278","article-title":"Adjuvant therapy with pembrolizumab in renal cell carcinoma: real-world experiences from a retrospective, multi-institutional cohort","volume":"109","author":"Mattigk","year":"2025","journal-title":"Urol Int"},{"key":"10.1016\/j.euo.2026.08.004_b0105","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1470-2045(22)00487-9","article-title":"Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Powles","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.08.004_b0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103603","article-title":"Accrual and statistical power failure in published adjuvant phase III oncology trials: a comprehensive analysis from 2013 to 2023","volume":"9","author":"Villacampa","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.euo.2026.08.004_b0115","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/annonc\/mdx743","article-title":"Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success?","volume":"29","author":"Figlin","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2026.08.004_b0120","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1007\/s00345-022-04153-6","article-title":"How to optimize the use of adjuvant pembrolizumab in renal cell carcinoma: which patients benefit the most?","volume":"40","author":"Fallara","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2026.08.004_b0125","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1002\/cncr.11234","article-title":"Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials","volume":"97","author":"Leibovich","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2026.08.004_b0130","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.3390\/cancers15092500","article-title":"Understanding the tumor immune microenvironment in renal cell carcinoma","volume":"15","author":"Shapiro","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.euo.2026.08.004_b0135","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/s41591-020-0839-y","article-title":"Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma","volume":"26","author":"Braun","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2026.08.004_b0140","doi-asserted-by":"crossref","first-page":"5959","DOI":"10.1038\/s41467-022-33555-8","article-title":"Molecular characterization of renal cell carcinoma tumors from a phase III anti-angiogenic adjuvant therapy trial","volume":"13","author":"Motzer","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.euo.2026.08.004_b0145","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.urolonc.2025.07.020","article-title":"Developing biomarkers and methods of risk stratification: consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank","volume":"43","author":"Shapiro","year":"2025","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2026.08.004_b0150","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.euf.2025.06.012","article-title":"KIM-1 as a prognostic marker in renal cell carcinoma","volume":"11","author":"Steiner","year":"2025","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2026.08.004_b0155","doi-asserted-by":"crossref","unstructured":"Shapiro DD, Nichols KD, Lee MH, et al. CXCL13-CXCR5 signaling in CD8+ T cell recruitment and lymphoid immune organization in clear cell renal cell carcinoma. Cancer Immunol Immunother. In press. https:\/\/doi.org\/10.1007\/s00262-026-04489-7.","DOI":"10.1007\/s00262-026-04489-7"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126002348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126002348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T20:40:42Z","timestamp":1789591242000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126002348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":31,"alternative-id":["S2588931126002348"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.08.004","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk-dependent Benefit of Adjuvant Pembrolizumab in High-risk Clear Cell Renal Cell Carcinoma: A Multi-institutional Study","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}